A Study to Evaluate the Efficacy and Safety of ALKS 2680 in Adults With Narcolepsy Type 2
A legfontosabb adatok
- Hol
- Austin, Boulder, Brandon, Charlotte, Cincinnati, Columbia, Cullman, Frisco, Huntersville, Kansas City, Lansing, Los Angeles, Macon, Maimi, Newton, Novi, Phoenix, Rochester, San Antonio, Stockbridge, Sugar Land, Winter Park és Wyomissing (Egyesült Államok)Mind a 23 helyszín megnézése
- Fázis
- 3. fázis
Neked szólhat?
Magadról válaszolj. Ez nem döntés: hogy részt vehetsz-e, azt csak a vizsgálat csapata mondhatja meg.
- 18 és 70 év között vagy?
Forrás: NCT07502443: ki vehet részt
Helyszínek itt: Egyesült Államok
- Austin, TexasHospital not named in the registryContact: Director Clinical Trial ManagerRésztvevőt keres
- Boulder, ColoradoHospital not named in the registryContact: Director Clinical Trial ManagerRésztvevőt keres
- Brandon, FloridaHospital not named in the registryContact: Director Clinical Trial ManagerRésztvevőt keres
- Charlotte, North CarolinaHospital not named in the registryContact: Director Clinical Trial ManagerRésztvevőt keres
- Cincinnati, OhioHospital not named in the registryContact: Director Clinical Trial ManagerRésztvevőt keres
- Columbia, South CarolinaHospital not named in the registryContact: Director Clinical Trial ManagerRésztvevőt keres
- Cullman, AlabamaHospital not named in the registryContact: Director Clinical Trial ManagerRésztvevőt keres
- Frisco, TexasHospital not named in the registryContact: Director Clinical Trial ManagerRésztvevőt keres
- Huntersville, North CarolinaHospital not named in the registryContact: Director Clinical Trial ManagerRésztvevőt keres
- Kansas City, KansasHospital not named in the registryContact: Director Clinical Trial ManagerRésztvevőt keres
- Lansing, MichiganHospital not named in the registryContact: Director Clinical Trial ManagerToborzás még nem indult
- Los Angeles, CaliforniaHospital not named in the registryContact: Director Clinical Trial ManagerRésztvevőt keres
- Macon, GeorgiaHospital not named in the registryContact: Director Clinical Trial ManagerRésztvevőt keres
- Maimi, FloridaHospital not named in the registryContact: Director Clinical Trial ManagerRésztvevőt keres
- Newton, MassachusettsHospital not named in the registryContact: Director Clinical Trial ManagerRésztvevőt keres
- Novi, MichiganHospital not named in the registryContact: Director Clinical Trial ManagerRésztvevőt keres
- Phoenix, ArizonaHospital not named in the registryContact: Director Clinical Trial ManagerRésztvevőt keres
- Rochester, MinnesotaHospital not named in the registryContact: Director Clinical Trial ManagerRésztvevőt keres
- San Antonio, TexasHospital not named in the registryContact: Director Clinical Trial ManagerRésztvevőt keres
- Stockbridge, GeorgiaHospital not named in the registryContact: Director Clinical Trial ManagerRésztvevőt keres
- Sugar Land, TexasHospital not named in the registryContact: Director Clinical Trial ManagerRésztvevőt keres
- Winter Park, FloridaHospital not named in the registryContact: Director Clinical Trial ManagerRésztvevőt keres
- Wyomissing, PennsylvaniaHospital not named in the registryContact: Director Clinical Trial ManagerRésztvevőt keres
Kérdések a vizsgálat csapatának
- Milyen gyakran kell bejárnom, és egy-egy alkalom mennyi ideig tart?
- Megtérítik az utazási költséget?
- Megtarthatom a saját orvosomat?
- Mi történik, ha ki akarok lépni?
Contact the study team: see the registry record → Contacts and Locations
Oldal nyomtatása az orvosomnakA vizsgálat adatai
- Ki végzi
- Alkermes, Inc.
- Azonosító
- NCT07502443
- A regiszteradat frissítve
- 2026. október 7.
- Eredeti leírás
The purpose of this study is to measure decreases in daytime sleepiness, and disease symptoms in participants with Narcolepsy Type 2 (NT2) when taking ALKS 2680 tablets compared with placebo tablets.A teljes eredeti leírásKevesebb
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of ALKS 2680 in Adults With Narcolepsy Type 2 (Brilliance NT2 Study 303)
The purpose of this study is to measure decreases in daytime sleepiness, and disease symptoms in participants with Narcolepsy Type 2 (NT2) when taking ALKS 2680 tablets compared with placebo tablets.
Bevonási feltételek: Is willing and able, in the opinion of the Investigator, to understand and comply with protocol requirements, including the following: lifestyle considerations and restrictions, adherence to contraception guidance, adherence to actigraphy and diary requirements, if receiving treatment for OSA, adherence to primary OSA therapy over the 30 days prior to Visit 1, and throughout the study, including during overnight visits; Meets the diagnostic criteria of NT2 according to ICSD-3-TR guidelines, confirmed by diagnostic evaluations (either PSG/MSLT).
Kizáró feltételek: Is currently enrolled in another interventional clinical trial or has received any investigational drug or used any interventional investigational device within 30 days prior to Visit 1. Participants previously enrolled in Study ALKS 2680-202 are not eligible for enrollment; Has another comorbid sleep disorder or condition that may influence the sleep-wake cycle; Has a history or presence of other clinically significant (treated or untreated) illness, disease, abnormality, or surgical procedure that, in the opinion of the Investigator, might compromise participant safety, interfere with any study assessment, or affect the participant's ability to complete the study; Is currently pregnant, breastfeeding, or is planning to become pregnant during the study.